-
-
-
AACR 2025 China ADC Achievements Overview
AACR
Explore key highlights from AACR 2025, where Chinese biotech firms showcased breakthroughs in ADC therapies, including dual-target, dual-payload innovations and promising clinical outcomes in solid tumor treatments.
-
PD-(L)1 Resistance Hope
PD-1
Explore how LRRC15+ CAFs contribute to PD-1 resistance, the role of LRRC15 in tumor immunity, and emerging therapies targeting LRRC15 and PD-1 to improve cancer immunotherapy outcomes.
-
Innovative Drugs: The Changing Times
FDA
Recent advancements in ADC therapies are reshaping cancer treatment. AstraZeneca and Gilead's breakthroughs in first-line therapies for breast and TNBC cancers mark a new era in innovative drug development.
-
Hengrui Pharmaceutical ADC Drug Overview
Hengrui
Hengrui has emerged as a leading force in ADC drug development, with a deep pipeline of 12 ADC drugs in clinical trials. Its proprietary HRMAP? platform and strategic innovations in targeting toxins and drug conjugation offer promising breakthroughs.
平定县|
济阳县|
体育|
砚山县|
松滋市|
大同县|
蒲城县|
方城县|
桦南县|
城步|
阿坝县|
通山县|
大宁县|
玉屏|
桃江县|
泗洪县|
高台县|
曲阜市|
五台县|
开平市|
庄河市|
冷水江市|
太仆寺旗|
长寿区|
古交市|
确山县|
康乐县|
丹江口市|
灵寿县|
胶南市|
曲水县|
静乐县|
平顶山市|
泾阳县|
冀州市|
舞阳县|
驻马店市|
林芝县|
板桥市|
高雄市|
秦皇岛市|